Annual Report

Overview

The report describes Venus Remedies’ strongest year to date, with consolidated revenue rising 17.87% and profit after tax exceeding H100 Crore. It highlights CDSCO approval for the Phase 1 clinical study of its lead anti-infective candidate, VRP-034, and progress in its research pipeline. The report also emphasizes increased manufacturing output using largely the same infrastructure and energy base, alongside the first full year of operations for Venus Foundation Trust.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2025-2026
Period: 1 April 2025 – 31 March 2026
Publication date: 24 July 2026
Language: English
Pages
File size
Restatement: Disclosed

Standards

Other

Materiality

Assessment
Basis

Assurance

Statement included

Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services